» Articles » PMID: 28652606

Interleukin 33 Exacerbates Antigen Driven Airway Hyperresponsiveness, Inflammation and Remodeling in a Mouse Model of Asthma

Overview
Journal Sci Rep
Specialty Science
Date 2017 Jun 28
PMID 28652606
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin 33 (IL-33) represents a potential link between the airway epithelium and induction of Th2-type inflammatory responses associated with the development of asthma. This study investigated the potential of IL-33 to exacerbate antigen driven asthma responses. An ovalbumin (OVA) asthma model was used in which sensitized C57BL/6 mice were exposed to IL-33 before each OVA challenge. IL-33 given to sensitized mice acted synergistically with antigen and aggravated airway inflammation, hyperresponsiveness and remodeling compared with mice that were only OVA sensitized and challenged and mice that were only exposed to IL-33. Elevated levels of local and systemic mast cell protease mMCP-1, as well as antigen-specific IgE production, were observed following IL-33 administration to sensitized mice. Similarly, exposing OVA-sensitized mice to IL-33 increased the Th2 cytokine levels, including IL-4, IL-5 and IL-13. Furthermore, IL-33 and OVA administration to OVA-sensitized mice increased ILC2s in the lung, suggesting a role for ILC2s in IL-33-mediated exacerbation of OVA-induced airway responses. Collectively, these findings show that IL-33 aggravates important features of antigen-driven asthma, which may have implications for asthma exacerbations.

Citing Articles

Persistent Neutrophilic Inflammation is Associated with Delayed Toxicity of Phenylarsine Oxide in Lungs.

Sanchez N, Mani G, Jones C, Zmijewsli J, Surolia R Res Sq. 2025; .

PMID: 39877099 PMC: 11774458. DOI: 10.21203/rs.3.rs-5100050/v1.


Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression.

Park J, Mortaja M, Son H, Zhao X, Sloat L, Azin M Nat Commun. 2024; 15(1):4099.

PMID: 38816352 PMC: 11139893. DOI: 10.1038/s41467-024-48441-8.


A mouse model of wildfire smoke-induced health effects: sex differences in acute and sustained effects of inhalation exposures.

Buford M, Lacher S, Slattery M, Levings D, Postma B, Holian A Inhal Toxicol. 2024; 36(6):367-377.

PMID: 38769076 PMC: 11298299. DOI: 10.1080/08958378.2024.2354398.


Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling.

Fields J, Gyllenback E, Bogacz M, Obi J, Birkedal G, Sjostrom K Cell Rep. 2024; 43(5):114099.

PMID: 38636519 PMC: 11587196. DOI: 10.1016/j.celrep.2024.114099.


Inserting "OFF-to-ON" BODIPY Tags into Cytokines: A Fluorogenic Interleukin IL-33 for Real-Time Imaging of Immune Cells.

Reese A, de Moliner F, Mendive-Tapia L, Benson S, Kuru E, Bridge T ACS Cent Sci. 2024; 10(1):143-154.

PMID: 38292608 PMC: 10823590. DOI: 10.1021/acscentsci.3c01125.


References
1.
Becker M, Reuter S, Friedrich P, Doener F, Michel A, Bopp T . Genetic variation determines mast cell functions in experimental asthma. J Immunol. 2011; 186(12):7225-31. DOI: 10.4049/jimmunol.1100676. View

2.
Makrinioti H, Toussaint M, Jackson D, Walton R, Johnston S . Role of interleukin 33 in respiratory allergy and asthma. Lancet Respir Med. 2014; 2(3):226-37. DOI: 10.1016/S2213-2600(13)70261-3. View

3.
Swedin L, Ellis R, Kemi C, Ryrfeldt A, Inman M, Dahlen S . Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness. Int Arch Allergy Immunol. 2010; 153(3):249-58. DOI: 10.1159/000314365. View

4.
Wenzel S . Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 18(5):716-25. DOI: 10.1038/nm.2678. View

5.
Enoksson M, Lyberg K, Moller-Westerberg C, Fallon P, Nilsson G, Lunderius-Andersson C . Mast cells as sensors of cell injury through IL-33 recognition. J Immunol. 2011; 186(4):2523-8. DOI: 10.4049/jimmunol.1003383. View